(NYSE: MNK) presented 11 posters with data on its investigational
opioid, MNK-155, an extended-release oral formulation of hydrocodone and
acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone
hydrochloride and acetaminophen) Extended-Release Tablets (CII), at
PAINWeek, September 2-6 in Las Vegas, Nevada.
for Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014 investment picks